
Staar Surgical (NSDQ:STAA) won regulatory approval from India’s Central Drugs Standard Control Organization for its LASIK eye surgery alternative, the Visian implantable collamer lens with CentraFlow.
Staar’s surgical vision correction procedure includes a "CentraFlow" feature that allows fluid to move easily within the eye. Typically, a patient would need to undergo peripheral iridotomy – a laser procedure that burns a hole through the iris – 2 days before a refractive eye surgery. CentraFlow eliminates the need for this pre-surgery procedure, according to a press release.
Monrovia, Calif.-based Staar, which recently won green lights in Korea and Argentina for the Visian implantable lens, is touting CentraFlow as a feature that enhances patient comfort compared to LASIK.
"We are delighted to add India to the growing list of markets in which we now have the CentraFlow technology to help drive market share growth in the Asia Pacific region," Don Todd, Asia Pacific regional president, said in prepared remarks. "With this approval in India, we can now leverage this growing acceptance to further penetrate a significantly large market."